It is unclear whether detection of prediabetes(Pre-DM) by routine assessment of glycated haemoglobin A1c(HbA1c) and fasting plasma glucose(FPG) among patients undergoing percutaneous coronary intervention(PCI) with contemporary drug-eluting stents(DES) may help identify subjects with increased event risk. We assessed the relation between glycaemia status and 1-year outcome after PCI.
INTRODUCTION
Before the onset of type 2 diabetes mellitus (DM), some patients can experience for many years an abnormal glucose metabolism which is a risk factor for coronary artery disease.
1,2 A metabolic state with borderline high glucose levels that do not meet the diabetes mellitus (DM) criteria is referred to as prediabetes(Pre-DM), although some prefer the term risk of diabetes. 3 Pre-DM can be detected by measuring glycated haemoglobin A1c(HbA1c), which
gives an indication of long-term blood glucose concentration, and fasting plasma glucose (FPG). 4, 5 Because HbA1c measurements do not require fasting or a glucose load, and are not affected by acute changes in glucose levels due tot stress or acute illness, they are easy to use in emergency settings and show only limited within-day or day-to-day variation. [4] [5] [6] [7] General population studies have investigated the association between cardiovascular risk and glucose abnormalities to a great extent, showing in subjects without known DM that elevated HbA1c is a risk factor for cardiovascular events. 2, 8 In addition, in patients, with or Disclaimer : As a public service to our readership, this article --peer reviewed by the Editors of EuroIntervention -has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal without known DM, who had an ST-elevation MI, elevated HbA1c levels were associated with increased mortality. 4, 9, 10 Moreover, DM increases the event risk after coronary stenting. [11] [12] [13] [14] [15] Nevertheless, there is a lack of data on the potential relevance of pre-DM for clinical outcome of all-comer patients with proven obstructive coronary disease, who require percutaneous treatment with current drug-eluting stents(DES).
The BIO-RESORT randomised trial recently examined the outcome of all-comer patients, who underwent percutaneous coronary intervention(PCI) with implantation of contemporary DES, showing similar and very low clinical event rates for all stents used. 16 In this prespecified analysis of the BIO-RESORT trial, we assessed the relation between Pre-DM and 1-year clinical outcome after PCI.
METHODS

Study design and patients
In the investigator-initiated, multicenter, randomised BIO-RESORT trial, all-comer patients were treated with PCI and contemporary biodegradable polymer or durable polymer DES.
Both design and primary outcome of BIO-RESORT, which is registered with ClinicalTrials.gov(NCT01674803), has been described previously. 16 All four clinical study sites, located in the Netherlands, were encouraged to determine in non-DM patients HbA1c levels at baseline in order to identify patients with Pre-DM or newly diagnosed DM, if no HbA1c levels were available the fasting plasma glucose levels were used. In addition, the presence of known DM was recorded in the study files. HbA1c was measured using Tinaquant 3rd generation assay on a Cobas 6000 analyser (Roche Diagnostics, Almere, the 
Glycaemic categories
Based on HbA1c and FPG levels measured at the index hospitalisation, and medical history, patients were stratified into three groups. Glycaemic categories were based on the National
Institute for Health and Care Excellence(NICE) 17 mmol/mol (³6.5%)(consistent with the IEC criteria). Sites were encouraged to assess the levels twice during hospitalization, in case of any discordance between the diagnostic tests, patients were classified into their 'worst' category based on their lab results.
Study endpoints, procedures, and monitoring
Clinical endpoints were pre-specified, using the Academic Research Consortium definitions. 16 Myocardial infarction was defined by any creatine kinase concentration of more than double the upper limit of normal with elevated confirmatory cardiac biomarkers. 19 Revascularisation procedures were considered clinically indicated, if the angiographic percent diameter stenosis of the then treated lesion was ≥50% in the presence of ischemic signs or symptoms, or if the diameter stenosis was ≥70% irrespective of ischemic signs or symptoms. 16, 19 The main composite clinical endpoint of the present study comprised (components in hierarchical order):
all cause death, myocardial infarction, or revascularisation. 16 Coronary interventions and concomitant medication did not differ from standard treatment Disclaimer : As a public service to our readership, this article --peer reviewed by the Editors of EuroIntervention -has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal and were performed according to current medical guidelines. 16 In general, dual anti-platelet were performed by an independent clinical research organization (Diagram, Zwolle, the Netherlands).
Statistical analyses
Data were reported as frequencies and percentages for dichotomous and categorical variables. Baseline characteristics of the study population are presented in Table 1 . The majority of participants were Caucasian (95%). Patients with Pre-DM and DM were significantly older and had a higher body mass index than normoglycemic patients. Furthermore, they had similar cardiovascular risk profiles with higher rates of hypertension, hypercholesterolemia, and previous myocardial infarction and coronary revascularisation than normoglycemic patients (Table 1) . Information on medication prior to hospitalisation and at discharge are provided in Webappendix T1.
Continues variables were expressed as mean±standard deviation(SD
RESULTS
From
Clinical outcome data are presented in Table 2 . The composite endpoint death, myocardial infarction or revascularisation at 1 year was met by 36(11.1%) pre-DM patients, 83(10.5%)
Disclaimer : As a public service to our readership, this article --peer reviewed by the Editors of EuroIntervention -has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal diabetic patients, and 106(5.7%) normoglycemic patients (p<0.001; Figure 1 ). The individual components are presented in Figure 2 A, B, and C. Mortality rates were higher in Pre-DM(2.8%) and DM(2.8%) than in normoglycemic patients(1.2%, p=0.006)( Fig.2A ). Similar revascularisation rates were found during 1-year follow-up in patients with pre-DM and patients with DM (5.2%, and 5.9%), which were significantly higher than revascularisation rates in normoglycemic patients (3.0%,p<0.001) (Fig.2C ).
Multivariate analysis demonstrated that Pre-DM was independently associated with the composite endpoint at 1-year follow-up: Pre-DM patients had a 2-times higher event risk than patients with normoglycaemia (adjusted HR 2.0, 95%CI:1.4-3.0). Adjusted hazard ratios are presented in Table 2 (unadjusted hazard ratios in Webappendix T2), there were no significant differences in 1-year event risk between patients with Pre-DM and DM. Revascularisation data on stent level can be found in Webappendix T3.
When the ADA definitions were applied, 906(30%) patients were classified as prediabetic with a composite endpoint rate of 8.4% (vs. 5.1% in normoglycemics and 10.6% in diabetics, p<0.001); further details are presented in the Webappendix T4.
DISCUSSION
Main findings
In the present prospective study in all-comers, treated with contemporary DES, Pre-DM at baseline was present in 14% of all non-DM patients. Patients with Pre-DM had higher death and revascularisation rates than normoglycemic patients, and the composite clinical endpoint rates were higher in patients with Pre-DM (11.1% versus 5.7%). Multivariate analysis demonstrated a 2-times higher event risk of death, MI and revascularisation in Pre-DM than normoglycaemia.
Patients with Pre-DM and DM showed similar higher risk profiles versus patients with
Disclaimer : As a public service to our readership, this article --peer reviewed by the Editors of EuroIntervention -has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal normoglycaemia, including an older age, higher BMI, and higher rates of hypertension, hypercholesterolemia, prior MI, and prior revascularisation. Most of these variables are components of the metabolic syndrome or linked to insulin resistance, suggesting that individuals with Pre-DM have a 'diabetic phenotype'. 20 Despite the use of contemporary DES, the rates of most clinical endpoints were at least as high in Pre-DM as in DM, which underlines that PCI patients with Pre-DM are prone to experience adverse clinical events. Our data suggest that in non-diabetic all-comer patients scheduled for PCI, routine assessment of HbA1c and FPG may be of great value.
Further studies are needed to corroborate our findings, but the ease of HbA1c and FPG testing, relative cheap cost and the pick-up of somewhere between 11% (using more conservative prediabetes criteria used in Europe) to 30% using the ADA criteria means that many patients at risk of diabetes and a small percentage (4%) with new diabetes are identified with relevant clinical implications for both groups.
Prediabetes and cardiovascular risk
Although oral glucose tolerance testing(OGTT) has been suggested as gold standard in the diagnosis of DM, 21 there has been an increased interest in HbA1c and cardiovascular risk. In 2008 the IEC, appointed by the ADA, the European Association for the Study of Diabetes, and the International Diabetes Federation, modified previous recommendations and suggested that HbA1c levels would represent a better diagnostic tool for DM than single measures of glucose concentration. 18 The IEC also recommended HbA1c of 6.0-6.4% (42-47mmol/mol) for the identification of an intermediate risk group, i.e. prediabetes, since identification of these individuals provides an opportunity for intervention through lifestyle modification and pharmacological interventions to prevent progression to diabetes. 18 Pragmatic considerations which support the use of HbA1c are that no fasting is required, and that it can be assessed anytime, even shortly after an acute event. This flexibility is different from FPG assessment, Disclaimer : As a public service to our readership, this article --peer reviewed by the Editors of EuroIntervention -has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal which (ideally) should be performed at least 4 days after an MI to account for the acute phase response. [4] [5] [6] [7] As to the comparison of glucose measures for the prediction of first-onset cardiovascular disease, results from a meta-analysis of patient-level data from 73 prospective studies suggests that the assessment of HbA1c is equal to or modestly better than the assessment of fasting, random, or post-load plasma glucose. 22 Several general population studies have been performed to evaluate associations between Pre-DM (according to different definitions) and cardiovascular events, finding an increased risk of composite cardiovascular events, coronary heart disease, stroke, and all cause mortality. 7, 8, 23 Previous studies on prediabetes and PCI outcomes with long-term mortality. 24 Only 9 of the studies included in this meta-analysis concerned studies in which patients were treated with PCI, of which the majority was treated with bare metal stents or POBA. We will highlight the largest of these studies.
A retrospective, observational study in 4,176 non-diabetic STEMI patients, showed that HbA1c levels were independently associated with adverse outcome at 1-year follow-up. 4 In contrast, a Chinese observational registry of STEMI patients with and without DM found that baseline HbA1c levels did not independently predict 30-day clinical outcome (90% had primary PCI with bare metal stents or DES). 25 Nevertheless, follow-up duration of was very short and event rates were low. 25 A single-centre study evaluated the relation between HbA1c
and major adverse cardiac events(MACE) in non-diabetic patients, who underwent elective PCI with balloon angioplasty or bare metal stent implantation. 26 The study showed that Disclaimer : As a public service to our readership, this article --peer reviewed by the Editors of EuroIntervention -has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal abnormal HbA1c was associated with significantly higher risk of MACE and target vessel revascularisation, although it should be noted that event rates were high, which can be explained by the use of bare metal stents. Another recently published retrospective cohort study assessed non-diabetic patients with ischemic heart disease treated with PCI in 2010, with a mean follow-up of 42 months, showing that prediabetes as determined by HbA1c was not associated with long-term adverse cardiovascular outcomes. 27 Again the majority of these patients(>60%) were treated with bare metal stents and groups were relatively small.
A secondary analysis of the EARLY ACS trial showed similar rates of Pre-DM as compared to our trial, in patients who were admitted to the hospital with non-ST-elevated acute coronary syndromes, either treated with PCI or CABG. Their primary outcome was a composite of all-cause death or myocardial infarction at 30-days, showing no significant differences in event rates in prediabetic patients as compared to diabetic patients.
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Added value and clinical implications
The previous studies discussed, assessed only specific subsets of PCI patients (i.e. patients with DM, elective patients, or STEMI patients), and generally used techniques or devices that have been greatly replaced (i.e.balloon angioplasty, bare metal stents, or first-generation DES). 4 ,24-28 Our current study, on the other hand, reports findings of a recent prospective multicentre PCI study in all-comers who were all treated with contemporary newer-generation DES. 16 The findings obtained in patients with Pre-DM, DM, and normoglycaemia, provide present-day evidence of the importance of Pre-DM for the clinical outcome of all-comer patients after PCI with contemporary DES.
Patients with coronary disease share risk factors with the metabolic syndrome and are therefore at an increased risk of developing DM. 5, 29 It is important to identify patients with an abnormal glycaemic state as early as possible in order to prevent (or delay) the onset of DM.
Routine assessment of glycaemic state in PCI patients may help identify patients with Pre-DM, who are at an increased risk of adverse events. Close follow-up of these patients appears Disclaimer : As a public service to our readership, this article --peer reviewed by the Editors of EuroIntervention -has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal to be warranted and particular attention should be paid to lifestyle counselling and/or pharmacological therapy to reduce the risk of developing DM, and intensified secondary prevention measure to prevent clinically apparent coronary artery disease (e.g.more aggressive lipid lowering and hypertension treatment). Furthermore, identification of patients with new diabetes can lead them to immediately gain the benefit of newer diabetes therapies that decrease MACE and mortality in patients with diabetes and cardiovascular disease.
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Limitations
Glycaemic state was known in 85% of the trial participants, while these proportions are reasonable, data from an even greater share of subjects would have been welcome. OGTT is a well-known method to assess glucose metabolism and has detected more patients with DM in the general population as well as in patients with coronary disease, which is why it ideally would have been assessed also in order to complement the findings of HbA1c and FPG measurements. However, OGTT is more labor intensive and onerous on patients, and thus more difficult to integrate into routine clinical practice. To ensure that results could be generalized as much as possible to common clinical settings, we based the diagnosis of pre-DM, and newly diagnosed DM on HbA1c or FPG values determined at admission. Only in subjects who had a single HbA1c or FPG value determined at the time of discharge, we used that value. For prediabetes there are currently no formal recommendations regarding repeating test for confirmation, however, in the present analysis, in 85% of the patients glycemic testing was performed twice to confirm the diagnosis. Iron deficiency anaemia may increase HbA1c levels; however, Pre-DM is still independently associated with the composite endpoint, despite including haemoglobin levels in the multivariate analysis. Finally, no data were available on the duration of DM before study enrolment or the occurrence of contrast-induced acute kidney injury, which count as predictors of worse prognosis. 
CONCLUSIONS
Following PCI with contemporary drug-eluting stents, all-comer patients with Pre-DM had a significantly higher risk of adverse events than normoglycemic patients. In a non-diabetic patient population with obstructive coronary artery disease, routine assessment of HbA1c prior to PCI may be of clinical value.
Impact on daily practice
Routine assessment of HbA1c and fasting plasma glucose in patients requiring PCI with contemporary DES, may help identify a specific subpopulation who are at increased risk of experiencing adverse events. Close follow-up of these patients appears to be warranted and particular attention should be paid to lifestyle counselling and/or pharmacological therapy to reduce the risk of developing DM, and to prevent clinically apparent coronary artery disease.
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